Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

Antidepressant-like effects of buprenorphine in rats are strain dependent

(2015) Caroline A. Browne et al.   BEHAVIOURAL BRAIN RESEARCH

Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system

(2015) Rachel J. Donahue et al.   BEHAVIOURAL PHARMACOLOGY

Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice

(2015) Abdulrahman Almatroudi et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single, Escalating Oral Doses of JDTic

(2015) Jeffrey J Buda et al.   NEUROPSYCHOPHARMACOLOGY

How fast and how often: The pharmacokinetics of drug use are decisive in addiction

(2015) Florence Allain et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans

(2015) Anya K. Bershad et al.   PSYCHONEUROENDOCRINOLOGY

Abnormal error processing in depressive states: a translational examination in humans and rats

(2015) C Beard et al.   Translational Psychiatry

Antagonists of the kappa opioid receptor

(2014) Mariangela Urbano et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

BU08073 a buprenorphine analogue with partial agonist activity at μ-receptorsin vitrobut long-lasting opioid antagonist activityin vivoin mice

(2014) T V Khroyan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults

(2014) Jordan F. Karp et al.   JOURNAL OF CLINICAL PSYCHIATRY

Circumspectives: The Promise of Ketamine

(2014) William A Carlezon et al.   NEUROPSYCHOPHARMACOLOGY

Evaluation of Opioid Modulation in Major Depressive Disorder

(2014) Elliot Ehrich et al.   NEUROPSYCHOPHARMACOLOGY

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

(2014) Edgardo Falcon et al.   PSYCHOPHARMACOLOGY

Development of κ Opioid Receptor Antagonists

(2013) F. Ivy Carroll et al.   JOURNAL OF MEDICINAL CHEMISTRY

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

(2013) Linda M. Rorick-Kehn et al.   NEUROPHARMACOLOGY

Prefrontal Cortical Kappa-Opioid Receptor Modulation of Local Neurotransmission and Conditioned Place Aversion

(2013) Hugo A Tejeda et al.   NEUROPSYCHOPHARMACOLOGY

Role of kappa-opioid receptors in stress and anxiety-related behavior

(2013) Ashlee Van’t Veer et al.   PSYCHOPHARMACOLOGY

Roles of Nucleus Accumbens CREB and Dynorphin in Dysregulation of Motivation

(2013) J. W. Muschamp et al.   Cold Spring Harbor Perspectives in Medicine

A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm

(2012) Sarah F. Cordery et al.   ADDICTION BIOLOGY

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety

(2012) Jesse R. Schank et al.   ADDICTION BIOLOGY

Stress Produces Aversion and Potentiates Cocaine Reward by Releasing Endogenous Dynorphins in the Ventral Striatum to Locally Stimulate Serotonin Reuptake

(2012) A. G. Schindler et al.   JOURNAL OF NEUROSCIENCE

Corticotropin-Releasing Factor (CRF)-Induced Disruption of Attention in Rats Is Blocked by the κ-Opioid Receptor Antagonist JDTic

(2012) Ashlee Van'T Veer et al.   NEUROPSYCHOPHARMACOLOGY

A Combination of Buprenorphine and Naltrexone Blocks Compulsive Cocaine Intake in Rodents Without Producing Dependence

(2012) S. Wee et al.   Science Translational Medicine

Kappa Opioid Receptor Signaling in the Basolateral Amygdala Regulates Conditioned Fear and Anxiety in Rats

(2011) Allison T. Knoll et al.   BIOLOGICAL PSYCHIATRY

Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward Sensitivity

(2011) David N. Potter et al.   BIOLOGICAL PSYCHIATRY

Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity

(2011) Matthew F. Peters et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Activation of CREB in the Nucleus Accumbens Shell Produces Anhedonia and Resistance to Extinction of Fear in Rats

(2011) J. W. Muschamp et al.   JOURNAL OF NEUROSCIENCE

Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats

(2011) Elena Chartoff et al.   NEUROPHARMACOLOGY

Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders

(2010) Thomas Insel et al.   AMERICAN JOURNAL OF PSYCHIATRY

How to improve R&D productivity: the pharmaceutical industry's grand challenge

(2010) Steven M. Paul et al.   NATURE REVIEWS DRUG DISCOVERY

CRF1-R Activation of the Dynorphin/Kappa Opioid System in the Mouse Basolateral Amygdala Mediates Anxiety-Like Behavior

(2010) Michael R. Bruchas et al.   PLoS One

The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse

(2010) Sunmee Wee et al.   PSYCHOPHARMACOLOGY

Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats

(2010) Gregory V. Carr et al.   PSYCHOPHARMACOLOGY

Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens

(2010) Stephanie R. Ebner et al.   PSYCHOPHARMACOLOGY

Dynorphin, stress, and depression

(2009) Allison T. Knoll et al.   BRAIN RESEARCH

The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors

(2009) M.R. Bruchas et al.   BRAIN RESEARCH

kappa-Opioid receptor signaling and brain reward function

(2009) Adrie W. Bruijnzeel   BRAIN RESEARCH REVIEWS

Perspective: Progress on the Study and Treatment of Depressive Illness

(2009) William A Carlezon et al.   NEUROPSYCHOPHARMACOLOGY

Kappa-opioid ligands in the study and treatment of mood disorders

(2009) William A. Carlezon et al.   PHARMACOLOGY & THERAPEUTICS

Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action

(2009) J. V. Aldrich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation Reward

(2008) Hilarie C. Tomasiewicz et al.   BIOLOGICAL PSYCHIATRY

Potential of Buprenorphine/Naltrexone in Treating Polydrug Addiction and Co-occurring Psychiatric Disorders

(2008) DJ McCann   CLINICAL PHARMACOLOGY & THERAPEUTICS

Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy

(2008) Peter W. Nyhuis et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin  -Opioid System

(2008) B. B. Land et al.   JOURNAL OF NEUROSCIENCE

Desipramine Reduces Stress-Activated Dynorphin Expression and CREB Phosphorylation in NAc Tissue

(2008) E. H. Chartoff et al.   MOLECULAR PHARMACOLOGY

Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis

(2008) William A. Carlezon et al.   NEUROPHARMACOLOGY